Dutch companies Batavia Bioservices and Xendo have announced a strategic business collaboration providing Batavia Bioservices with access to Xendo?s simulated moving bed purification technology.
Dutch companies Batavia Bioservices and Xendo have announced a strategic business collaboration providing Batavia Bioservices with access to Xendo’s simulated moving bed purification technology. All bioprocess activities of Xendo have been transferred and the company will also provide infrastructure, knowledge and experience in microbial process and product development.
Menzo Havenga, CEO of Batavia Bioservices, explains: "It is fully expected that our collaboration will result in more customers being offered a complete development services package.”
The companies have also announced that they will also establish joint marketing efforts whereby Xendo BV will provide engineering, regulatory and clinical support services and Batavia Bioservices will provide process development and analytical services.
André van de Sande, CEO of Xendo, adds, “I trust that by combining our forces both companies are better positioned to service our customers. This helps Xendo, both in the Netherlands and internationally, to further expand."
For more information on the companies, visit their websites at www.bataviabioservices.com and www.xendo.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.